Published in Immunogenetics on February 01, 2000
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A (2004) 2.58
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood (2007) 2.29
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica (2010) 1.27
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant (2008) 1.13
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood (2010) 1.09
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist (2012) 1.07
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.06
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia (2013) 1.05
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods (2008) 1.03
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica (2009) 1.00
Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol (2000) 0.96
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother (2014) 0.95
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res (2012) 0.95
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol (2007) 0.92
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol (2015) 0.92
Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem (2013) 0.92
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin Immunol (2010) 0.89
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
RNA vaccines in cancer treatment. J Biomed Biotechnol (2010) 0.87
The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers. Int J Oncol (2014) 0.87
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids (2013) 0.86
Non-natural and photo-reactive amino acids as biochemical probes of immune function. PLoS One (2008) 0.85
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother (2011) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant (2014) 0.84
Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood (2011) 0.82
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci (2010) 0.80
Virosome presents multimodel cancer therapy without viral replication. Biomed Res Int (2013) 0.80
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2011) 0.78
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol (2011) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther (2009) 0.77
Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. J Mol Biol (2015) 0.77
Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. Immunology (2015) 0.76
Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology (2003) 0.76
Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells. Clin Immunol (2016) 0.76
A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells. J Immunother (2016) 0.75
Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts. J Immunother (2016) 0.75
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer (2016) 0.75
Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines (Basel) (2015) 0.75
Adoptive Immunotherapy for Leukemia with Ex Vivo Expanded T Cells. Curr Drug Targets (2015) 0.75
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol (2001) 12.56
Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell (1992) 10.78
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Tree allometry and improved estimation of carbon stocks and balance in tropical forests. Oecologia (2005) 10.52
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature (2000) 9.44
Modular chemistry: secondary building units as a basis for the design of highly porous and robust metal-organic carboxylate frameworks. Acc Chem Res (2001) 9.19
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Regulatory element detection using correlation with expression. Nat Genet (2001) 8.92
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Notch signalling controls pancreatic cell differentiation. Nature (1999) 7.18
Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature (1996) 7.11
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol (2001) 7.08
Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J (1998) 6.65
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Mechanical unfolding intermediates in titin modules. Nature (1999) 6.12
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest (2001) 4.98
Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat Genet (1993) 4.96
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Organization of the recA gene of Escherichia coli. Proc Natl Acad Sci U S A (1980) 4.90
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl Environ Microbiol (2001) 4.59
Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature (2001) 4.55
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
A mouse model for spinal muscular atrophy. Nat Genet (2000) 4.37
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2000) 4.02
Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res (2001) 3.89
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res (2000) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Complex formation and functional versatility of Mre11 of budding yeast in recombination. Cell (1998) 3.80
A simple method for determining the modulation transfer function in digital radiography. IEEE Trans Med Imaging (1992) 3.79
Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res (1999) 3.69
A DNA damage response pathway controlled by Tel1 and the Mre11 complex. Mol Cell (2001) 3.65
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 3.63
Nucleotide sequence of the lexA gene of E. coli. Cell (1981) 3.61
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
Characterization of Y73, an avian sarcoma virus: a unique transforming gene and its product, a phosphopolyprotein with protein kinase activity. Proc Natl Acad Sci U S A (1980) 3.58
Interaction of Mre11 and Rad50: two proteins required for DNA repair and meiosis-specific double-strand break formation in Saccharomyces cerevisiae. Genetics (1995) 3.57
Studies on radiation-sensitive mutants of E. coli. I. Mutants defective in the repair synthesis. Mol Gen Genet (1968) 3.55
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation (1999) 3.41
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med (1999) 3.38
Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33
cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature (1987) 3.31
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
ADP-ribosylation. Annu Rev Biochem (1985) 3.30
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell (1998) 3.20
Building a dictionary for genomes: identification of presumptive regulatory sites by statistical analysis. Proc Natl Acad Sci U S A (2000) 3.18
Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat Struct Biol (1997) 3.14
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Cinemicrographic study of tissue cell cultures infected with Shigella flexneri. Jpn J Med Sci Biol (1968) 3.12
Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr Biol (2001) 3.09
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol (1999) 3.08
Poly(ADP-ribose) and ADP-ribosylation of proteins. Annu Rev Biochem (1977) 3.08
IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 3.08
An essential gene, ESR1, is required for mitotic cell growth, DNA repair and meiotic recombination in Saccharomyces cerevisiae. Nucleic Acids Res (1994) 3.05
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Mechanical design of proteins studied by single-molecule force spectroscopy and protein engineering. Prog Biophys Mol Biol (2000) 3.00
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology (1995) 2.99
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
Simple method for quantitation of enhanced vascular permeability. Proc Soc Exp Biol Med (1970) 2.93
Characteristics of purified recA protein and the regulation of its synthesis in vivo. Cold Spring Harb Symp Quant Biol (1979) 2.93
Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature (1995) 2.91
Clostridium botulinum neurotoxin. Microbiol Rev (1980) 2.89